Physician profile
Daniel Y Lin
NPI 1073781621
$1,943.81
in general payments reported to CMS, 2019-2025
31 companies · $602 in 2025
The $602 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $59.33 · 2021: $184 · 2022: $165 · 2023: $477 · 2024: $456 · 2025: $602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,535.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,535.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $681.68 | 2020-2025 | |
| Exact Sciences Corporation | $236.78 | 2023-2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $169.44 | 2024-2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.53 | 2024-2025 | Jardiance |
| Ultragenyx Pharmaceutical INC. | $82.38 | 2021-2022 | |
| Novo Nordisk INC | $56.96 | 2024-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $49.61 | 2021-2025 | Airsupra |
| Amgen INC. | $44.50 | 2025 | Repatha, Evenity, Prolia |
| Ani Pharmaceuticals, INC. | $43.21 | 2025 | Purified Cortrophin Gel |
| Phathom Pharmaceuticals, INC. | $42.90 | 2023-2025 | Voquezna |
| Abbvie INC. | $41.99 | 2024-2025 | |
| Kowa Pharmaceuticals America, INC. | $33.50 | 2024-2025 | Zoryve |
| Aurinia Pharma U.S., INC. | $30.00 | 2023 | Lupkynis |
| Regeneron Healthcare Solutions, INC. | $27.58 | 2023 | Libtayo |
| Novartis Pharmaceuticals Corporation | $24.67 | 2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $24.49 | 2025 | |
| Pharmacosmos Therapeutics INC. | $23.08 | 2025 | Monoferric |
| Idorsia Pharmaceuticals US INC | $22.20 | 2023 | Quviviq |
| Phadia US INC. | $22.17 | 2022 | |
| Xeris Pharmaceuticals, INC. | $21.37 | 2023 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $19.25 | 2020 | |
| Shield Therapeutics INC | $18.64 | 2025 | |
| Vbi Vaccine (Delaware) INC. | $18.49 | 2023 | Prehevbrio |
| Meridian Bioscience INC. | $18.20 | 2024 | |
| Sun Pharmaceutical Industries INC. | $18.09 | 2020 | |
| Lilly USA, LLC | $18.00 | 2025 | Jardiance |
| Paratek Pharmaceuticals, INC. | $17.53 | 2025 | Nuzyra |
| Merck Sharp & Dohme LLC | $17.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.72 | 2024 | Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $13.85 | 2023 | Gattex |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.